tyrphostins - CISMeF

Preferred Label : tyrphostins;

MeSH definition : A family of synthetic protein tyrosine kinase inhibitors. They selectively inhibit receptor autophosphorylation and are used to study receptor function.;

MeSH synonym : Tyrphostin;

Wikipedia link : https://en.wikipedia.org/wiki/Tyrphostins;

Is substance : O;

Détails

Origin ID

D020032;

UMLS CUI

C0600438;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Pharmacological action(s)
- antineoplastic agents [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
Record concept(s)
- tyrphostins [MeSH concept]
Related MeSH Supplementary Concept(s)
- 3-methoxyl-5-(2-,2-dicyanoethenyl)catechol [MeSH Supplementary Concept]
- 4-nitrobenzylidene malononitrile [MeSH Supplementary Concept]
- 6,7-dimethoxy-2-phenylquinoxaline [MeSH Supplementary Concept]
- 6,7-dimethoxy-3-phenylquinoxaline [MeSH Supplementary Concept]
- AG 127 [MeSH Supplementary Concept]
- AG 183 [MeSH Supplementary Concept]
- AG 30 [MeSH Supplementary Concept]
- AG 372 [MeSH Supplementary Concept]
- AG 494 [MeSH Supplementary Concept]
- AG 538 [MeSH Supplementary Concept]
- AG 556 [MeSH Supplementary Concept]
- AG-879 [MeSH Supplementary Concept]
- AG1801 [MeSH Supplementary Concept]
- AGL2019 [MeSH Supplementary Concept]
- RG 13022 [MeSH Supplementary Concept]
- RG 14620 [MeSH Supplementary Concept]
- RTKI cpd [MeSH Supplementary Concept]
- Ryngo 1-23 [MeSH Supplementary Concept]
- WP1066 [MeSH Supplementary Concept]
- alpha-cyano-(3,4-dihydroxy)-N-(3-phenylpropyl)cinnamide [MeSH Supplementary Concept]
- alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide [MeSH Supplementary Concept]
- tyrphostin 11 [MeSH Supplementary Concept]
- tyrphostin 25 [MeSH Supplementary Concept]
- tyrphostin 47 [MeSH Supplementary Concept]
- tyrphostin 51 [MeSH Supplementary Concept]
- tyrphostin 8 [MeSH Supplementary Concept]
- tyrphostin A23 [MeSH Supplementary Concept]
- tyrphostin A46 [MeSH Supplementary Concept]
- tyrphostin A51 [MeSH Supplementary Concept]
- tyrphostin A9 [MeSH Supplementary Concept]
- tyrphostin AG 1024 [MeSH Supplementary Concept]
- tyrphostin AG 1109 [MeSH Supplementary Concept]
- tyrphostin AG 1112 [MeSH Supplementary Concept]
- tyrphostin AG 114 [MeSH Supplementary Concept]
- tyrphostin AG 126 [MeSH Supplementary Concept]
- tyrphostin AG 1394 [MeSH Supplementary Concept]
- tyrphostin AG 568 [MeSH Supplementary Concept]
- tyrphostin AG 814 [MeSH Supplementary Concept]
- tyrphostin AG34 [MeSH Supplementary Concept]
- tyrphostin AG825 [MeSH Supplementary Concept]
- tyrphostin AG957 [MeSH Supplementary Concept]
- tyrphostin AGL-2043 [MeSH Supplementary Concept]
- tyrphostin B44 [MeSH Supplementary Concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients